MassHIWay: An Update on the Massachusetts HIE
The quality measurement demonstration is part of the requirements to meet Meaningful Use Stage 2 and includes syndromic surveillance, immunization, and daily lab data.
John Halamka, CIO of the CareGroup HealthSystem reported on the HIE’s progress in a recent contribution to Healthcare IT News.
We expect the pace of adoption to grow exponentially as organizations prepare for Meaningful Use Stage 2 attestation and must exchange transition of care summaries for 10% of their patient visits.
continue reading | via Healthcare IT News